T-cell lymphoma >  Mogamulizumab (call it Mogo) targets CCR4

Last update: 06/01/2013

Here's another antibody with a challenging ame. This one looks promising for the treatment of t-cell lymphomas that express the target.

Mogamulizumab (call it Mogo) targets CCR4 ...
a chemokine involved in the migration and homing of leukocytes.

ASCO 2013 report:

Randomized phase II study of mogamulizumab (KW-0761) plus chemo versus chemo alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). http://meetinglibrary.asco.org/abstractbysubcategory/2013%20ASCO%20Annual%20Meeting/114  Note that expression of the target was required for eligibility: Previously untreated patients (pts) with CCR4-positive ATL randomly assigned to receive mLSG15 (chemo) plus Moga (arm A) or mLSG15 (chemo) alone (arm B)

CR %:
Arm A: 52% (Confidence Interval 33, 71)
vs. Arm B: 33% (Confidence Interval 16, 55) and

ORR %:
Arm A: 86% (CI; 63, 96)
vs. Arm B: 75% (CI; 53, 90), respectively.

Note the wide confidence interval - which is due to the small study size - the best researcher can do because of the low incidence of the disease.

Technical background on target of mogamulizumab (Mogo):

Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425744/  snips: Chemokines act as signaling molecules in the migration and tissue homing of various leukocytes. Mogamulizumab/KW-0761 is a humanized monoclonal antibody that recognizes the N-terminal region of human CCR4 CC chemokine receptor 4 (CCR4) is expressed in various types of PTCL including adult T-cell leukemia-lymphoma (ATL), which has the worst prognosis among them. A phase II study of a defucosylated, humanized anti-CCR4 monoclonal antibody, mogamulizumab (KW-0761), yielded an overall response rate of 50 % (13/26) and a median progression-free survival of 5.2 months in relapsed patients with CCR4-positive ATL who had been previously treated with chemotherapy. Mogamulizumab also showed potential efficacy for cutaneous T-cell lymphoma in a US phase I/II study. Further preclinical and clinical investigations are needed to examine whether concomitant use of this novel agent with other agents with different mechanisms of action would be more effective for ATL and other PTCLs.

To find trials for this agent,

http://lymphomation.org/ctlookup-antibodies.htm#antibodies (last antibody in the list)